Vesicare (Solifenacin) Withdrawal Symptoms
There are no documented withdrawal symptoms from discontinuing Vesicare (solifenacin), as it is not associated with physical dependence or withdrawal syndrome. When stopping solifenacin, patients will simply experience a return of their original overactive bladder symptoms rather than true withdrawal effects.
What Happens When You Stop Vesicare
When discontinuing solifenacin, expect the following:
Return of Original OAB Symptoms
- Urgency episodes will return to baseline levels (typically within days to weeks)
- Urinary frequency will increase back to pre-treatment levels
- Urge incontinence episodes will recur if present before treatment
- Nocturia will return to baseline frequency
The FDA drug label 1 does not mention any withdrawal syndrome, discontinuation symptoms, or need for tapering when stopping solifenacin. This is consistent with the pharmacology of antimuscarinic medications, which do not cause physical dependence.
Key Clinical Points
No Tapering Required
- Solifenacin can be stopped abruptly without medical risk
- The FDA label 1 states: "If you miss a dose of VESIcare, begin taking VESIcare again the next day. Do not take 2 doses of VESIcare the same day"
- This guidance confirms no physiological dependence exists
Timeline of Symptom Return
Based on solifenacin's pharmacokinetics 2:
- Terminal half-life: 33-85 hours (approximately 1.4-3.5 days)
- Time to steady-state elimination: 5-7 days after last dose
- OAB symptom recurrence: Typically begins within 2-7 days as drug levels decline
- Full return to baseline: Usually complete within 1-2 weeks
What Patients May Experience (Not True Withdrawal)
Anticholinergic Effect Resolution:
- Dry mouth resolves (was present in 21.4% during treatment 3)
- Constipation improves (occurred in 13.3% during treatment 3)
- Blurred vision normalizes if present
- Normal sweating returns
OAB Symptom Recurrence:
- Urgency episodes increase by approximately 4.4 episodes/24 hours 4
- Frequency increases by approximately 3.6 episodes/24 hours 4
- Nocturia increases by approximately 1.4 episodes/24 hours 4
Important Caveats
Distinguish from True Withdrawal
Patients may perceive symptom return as "withdrawal," but this represents:
- Loss of therapeutic effect rather than physiological withdrawal
- Return to disease baseline not a rebound phenomenon
- No hyperactive state beyond original OAB severity
High Discontinuation Rates in Practice
Real-world data shows 5:
- 18.4% of patients discontinue solifenacin between visits
- Most discontinuations occur due to dissatisfaction with efficacy (persistence of symptoms during treatment)
- Only 1.6% discontinue due to adverse events 3
- This suggests most patients who stop do so because symptoms weren't adequately controlled, not due to intolerable side effects
When to Consider Alternative Management
If stopping solifenacin due to inadequate response:
- Combination therapy with mirabegron may be superior to monotherapy 6, 7
- Consider dose escalation from 5 mg to 10 mg before discontinuing (though this increases dry mouth risk 8)
- Evaluate for bladder outlet obstruction in men before assuming treatment failure
Clinical Bottom Line
Patients can safely stop Vesicare without tapering or risk of withdrawal syndrome. The only consequence is gradual return of overactive bladder symptoms over 1-2 weeks as the medication clears from the system. Any symptoms experienced represent the underlying OAB condition re-emerging, not a drug withdrawal effect. Patients should be counseled that this symptom return is expected and does not indicate harm from stopping the medication.